Ratio Therapeutics raised $70 million in a Series C to advance radiopharmaceutical trials, according to the company’s disclosed deal terms. The funding included both existing investors—Duquesne Family Office and Bristol Myers Squibb—and new backers, with the stated purpose to support the next steps in its radiopharma pipeline. In parallel, Vogenx signaled intent to go public, adding to a set of recent capital-market moves in mid-stage biotech.